A Study of MK0359 in Patients With Chronic Asthma (0359-013)
NCT ID: NCT00482898
Last Updated: 2015-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
56 participants
INTERVENTIONAL
2002-09-30
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
NCT00404313
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
NCT01370317
MK0524 Asthma POC Study (0524-008)(COMPLETED)
NCT00783601
A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)
NCT01343407
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
NCT00603382
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0359
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* You have had a history for at least a year of COPD symptoms
* Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)
* You have a history of smoking one pack of cigarettes per day for 7 years
* You will not be away from home for more than 5 days during the study
Exclusion Criteria
* You have been in a research study with an investigational drug or vaccine in the last 4 weeks
* You have donated blood in the last 4 weeks
* You have been hospitalized or had major surgery in the last 4 weeks
* You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma
* You have a history of heart problems in the last 6 months
* You have a history of stomach problems
* You are unwilling to avoid grapefruit juice throughout the study
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
References
Explore related publications, articles, or registry entries linked to this study.
Lu S, Liu N, Dass SB, Reiss TF, Knorr BA. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med. 2009 Mar;103(3):342-7. doi: 10.1016/j.rmed.2008.10.024. Epub 2009 Jan 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK0359-013
Identifier Type: -
Identifier Source: secondary_id
2007_575
Identifier Type: -
Identifier Source: secondary_id
0359-013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.